The Korea Herald CENTER (0.0) Reliability: 7.0/10

Celltrion launches first Xolair biosimilar in Brazil

✍️ Jang Hae-Rin 📅 November 27, 2025 05:50 AM ⏱️ 1 min read 🕐 Scraped: November 27, 2025

Summary: Celltrion launched its allergy treatment Omlyclo (omalizumab) in Brazil on Thursday, marking the first time a Xolair biosimilar has entered Latin America’s larg

Celltrion launched its allergy treatment Omlyclo (omalizumab) in Brazil on Thursday, marking the first time a Xolair biosimilar has entered Latin America’s largest pharmaceutical market.

Omlyclo is the first biosimilar of Xolair, a globa

📰

Continue Reading on The Korea Herald

This preview shows approximately 15% of the article. Read the full story on the publisher's website to support quality journalism.

Read Full Article →

How do you feel about this article?

Read Original Article →

📝 Article Information

Author

Jang Hae-Rin

Original Publisher

🌍 The Korea Herald

CENTER Bias (0.0)

Published Date

November 27, 2025 at 05:50 AM

ℹ️

Disclaimer

ArkforgeAI.com - Newsource is a news aggregation platform. We do not create, write, or produce original news content. All articles are sourced from their respective publishers and remain the property of their original creators. We analyze and aggregate news from multiple sources to provide diverse perspectives across the political spectrum.

The content displayed here is for informational purposes only. For the complete and original article, please visit the source's website using the "Read Original Article" link above.